公司资料
Zura Bio 股价、新闻与催化剂
- 股票代码:
- ZURA
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
5.68 USD (+1.97%)
收盘价
最后更新: 2026年8月17日
389M USD
市值
股价为何变动
As of Aug 17, 2026, ZURA closed up 1.97% at $5.68. No new same-company headline was identified in the current news window.
公司概览
Autoimmune and Inflammatory Diseases
Zura Bio develops biologics for serious autoimmune and inflammatory diseases, emphasizing combinations of validated immune pathways in single molecules.
Tibulizumab
Tibulizumab is a bispecific antibody designed to neutralize both IL-17 and BAFF. The dual mechanism targets inflammatory and B-cell biology involved in chronic immune-mediated disease.
TibuSHIELD
The Phase 2 TibuSHIELD study evaluates tibulizumab in adults with hidradenitis suppurativa, an inflammatory skin disease driven in part by IL-17 signaling.
TibuSURE
The Phase 2 TibuSURE study evaluates tibulizumab in adults with systemic sclerosis, where simultaneous IL-17 and BAFF inhibition may address inflammation, autoantibodies, and fibrosis.
NEXUS-PMR
Zura selected polymyalgia rheumatica as a third indication for tibulizumab. The planned Phase 2 NEXUS-PMR study extends the program into an inflammatory disorder commonly treated with long-term glucocorticoids.
未来催化剂
- Topline data from the Phase 2 TibuSHIELD study in the fourth quarter of 2026.
- Initiation of the Phase 2 NEXUS-PMR study by the end of 2026.
- Topline data from the Phase 2 TibuSURE study in the first half of 2027.
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。